AR118780A1 - THERAPEUTICS OF FULLY HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODIES - Google Patents
THERAPEUTICS OF FULLY HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODIESInfo
- Publication number
- AR118780A1 AR118780A1 ARP200101169A ARP200101169A AR118780A1 AR 118780 A1 AR118780 A1 AR 118780A1 AR P200101169 A ARP200101169 A AR P200101169A AR P200101169 A ARP200101169 A AR P200101169A AR 118780 A1 AR118780 A1 AR 118780A1
- Authority
- AR
- Argentina
- Prior art keywords
- fully human
- translationally modified
- methods
- post
- therapeutics
- Prior art date
Links
Abstract
Se proporcionan métodos y composiciones para la administración de anticuerpos monoclonales terapéuticos postraduccionalmente modificados, completamente humanos y los fragmentos de unión a antígeno de los mismos. Los anticuerpos monoclonales terapéuticos postraduccionalmente modificados, completamente humanos pueden administrarse mediante métodos de terapia génica, por ejemplo, como un vector de virus recombinante adenoasociado (rAAV) al tejido apropiado. También se proporcionan métodos de preparación de los vectores AAV, composiciones farmacéuticas y métodos de tratamiento. Además, se proporcionan métodos para producir anticuerpos terapéuticos que están “biomejorados” como completamente humanos, postraduccionalmente modificados. Estos anticuerpos terapéuticos postraduccionalmente modificados, completamente humanos pueden administrarse a un sujeto que necesita tratamiento con el anticuerpo terapéutico.Methods and compositions are provided for the administration of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human, post-translationally modified therapeutic monoclonal antibodies can be delivered by gene therapy methods, for example, as a recombinant adeno-associated virus (rAAV) vector to the appropriate tissue. Also provided are methods of preparing the AAV vectors, pharmaceutical compositions, and methods of treatment. In addition, methods are provided for producing therapeutic antibodies that are post-translationally modified as fully human "bi-enhanced". These fully human, post-translationally modified therapeutic antibodies can be administered to a subject in need of treatment with the therapeutic antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838165P | 2019-04-24 | 2019-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118780A1 true AR118780A1 (en) | 2021-10-27 |
Family
ID=78803872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101169A AR118780A1 (en) | 2019-04-24 | 2020-04-24 | THERAPEUTICS OF FULLY HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODIES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118780A1 (en) |
-
2020
- 2020-04-24 AR ARP200101169A patent/AR118780A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003888A (en) | Fully-human post-translationally modified antibody therapeutics. | |
| BR112021021156A2 (en) | Therapeutic post-translationally modified fully human antibodies | |
| BR112017008042A2 (en) | methods and compositions for dosage in adoptive cell therapy | |
| BR112018070676A2 (en) | multispecific antigen binding constructs that target immunotherapeutic agents | |
| MA47313A (en) | SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES | |
| MX2020003945A (en) | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap. | |
| NZ728265A (en) | Methods to enhance organ transplant and antibody therapies | |
| BR112022016657A2 (en) | BCMA CAR-T CELLS WITH IMPROVED ACTIVITIES | |
| Tyndall et al. | Stem cell transplantation and mesenchymal cells to treat autoimmune diseases | |
| MX2021001143A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof. | |
| PH12020551096A1 (en) | A modified raav capsid protein for gene therapy | |
| BR112021015751A2 (en) | Gene therapy vectors for the treatment of danon's disease | |
| CO2021016323A2 (en) | Compositions useful in the treatment of metachromatic leukodystrophy | |
| WO2017096327A3 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
| MX2021008958A (en) | Anti-il2 receptor gamma antigen-binding proteins. | |
| AR115721A1 (en) | ANTIBODIES INCLUDING A POLIPEPTIDE INSERTED IN THE FRAME 3 REGION | |
| BR112022015979A2 (en) | GENE THERAPY VECTORS FOR THE TREATMENT OF HEART DISEASES | |
| EA202193309A1 (en) | ANTIBODY TO TISSUE FACTOR-DRUG CONJUGATES AND RELATED METHODS | |
| Choi et al. | Transplantation of adipose tissue-derived mesenchymal stem cells prevents the development of lupus dermatitis | |
| MX2023004005A (en) | Formulations for suprachoroidal administration such as gel formulations. | |
| Fan et al. | Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis | |
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| EA202192160A1 (en) | DELIVERY OF POLYNUCLEOTIDE CLN3 USING AN ADENO-ASSOCIATED VIRUS | |
| MX2023004806A (en) | Vectorized anti-tnf-î± antibodies for ocular indications. | |
| AU2020294340B2 (en) | Compositions and methods for targeting of the surfactant protein a receptor |